Literature DB >> 27620494

Antibiotic-Induced Rash in Patients With Infectious Mononucleosis.

Dennis F Thompson1, Carroll L Ramos1.   

Abstract

OBJECTIVE: To provide an extensive review of case reports, epidemiological data, and the underlying mechanism of antibiotic-induced skin rash in patients with concurrent infectious mononucleosis (IM). DATA SOURCES: A MEDLINE literature search inclusive of the dates 1946 to June 2016 was performed using the search terms anti-bacterial agents and infectious mononucleosis. EMBASE (1980 to June 2016) was searched using the terms mononucleosis and antibiotic agent and drug eruption. References of all relevant articles were reviewed for additional citations and information. STUDY SELECTION AND DATA EXTRACTION: We selected English-language, primary literature, review articles, and mechanistic articles that addressed antibiotic-induced skin rash in patients with concurrent IM. We assessed all case reports available for causality utilizing a modified Naranjo nomogram specifically designed for this subject. We assembled the available epidemiological data into tables to identify trends in incidence rates over the years. DATA SYNTHESIS: We identified 17 case reports of antibiotic-associated rash in patients with IM. The median Naranjo score was 6 (range = 1 to 8). The top 3 reported drugs were ampicillin, azithromycin, and amoxicillin. Incidence of this adverse effect was higher in the 1960s (55.6%, 45%, and 33%) than in 2013 (33% and 15%). The mechanism most commonly proposed is a transient virus-mediated immune alteration that sets the stage for loss of antigenic tolerance and the development of a reversible, delayed-type hypersensitivity reaction to the antibiotic.
CONCLUSION: A reassessment of the long-held belief of the high incidence (80%-100%) of antibiotic-induced skin rash in patients with IM seems prudent. Additional studies will be necessary to clarify this issue.

Entities:  

Keywords:  adverse drug reactions; antibiotics; infectious disease; viral infections; β-lactams

Mesh:

Substances:

Year:  2016        PMID: 27620494     DOI: 10.1177/1060028016669525

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  3 in total

1.  Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19.

Authors:  Georg Franz Lehner; Sebastian Johann Klein; Heinz Zoller; Andreas Peer; Romuald Bellmann; Michael Joannidis
Journal:  Crit Care       Date:  2020-11-23       Impact factor: 9.097

2.  Difference between Acyclovir and Ganciclovir in the Treatment of Children with Epstein-Barr Virus-Associated Infectious Mononucleosis.

Authors:  Shouyuan Zhang; Yanyan Zhu; Yanyan Jin; Hong Sun; Weiqun Wang; Lu Zhan
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-20       Impact factor: 2.629

Review 3.  [Virus-induced exanthems in returning travellers].

Authors:  Luisa Bopp; Alexander Kreuter; Esther von Stebut; Mario Fabri
Journal:  Hautarzt       Date:  2022-05-13       Impact factor: 1.198

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.